Key Drivers
- Margin Stability
- Strong Cash Flow
- Rich Valuation
AIAI Summary
STERIS remains a high-quality compounder with strong margins, cash flow, and a solid balance sheet, but at ~39x earnings and ~19x EV/EBITDA the stock looks fully priced, so near-term upside now depends on flawless execution and proof that softer equipment/service trends do not widen into a growth slowdown.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Margin Stability
- •Strong Cash Flow
- •Rich Valuation
STE shows steady profitability and strong cash generation with improving liquidity, but its elevated valuation and intangible-heavy balance sheet limit upside.
Price Behavior
Key Price Behavior Insights:
- •Lower highs
- •Support rebound
- •Overhead supply
STE has trended lower over the last month, but a rebound from the $202 support zone suggests stabilization even as overhead resistance at $216-$226 keeps the setup fragile. ക
Rebounded from $201.85 to $215.98 after the recent low, signaling short-term stabilization
Sentiment & News
Key News Insights:
- •Strong annual growth
- •Slight quarterly miss
- •Positive FY27 outlook
STERIS ended fiscal 2026 with solid 7% revenue growth and record annual sales, and while Q4 slightly missed expectations, management's above-consensus fiscal 2027 outlook, steady procedure demand, and shareholder returns point to continued momentum.
The news is modestly positive for STERIS, as strong underlying demand and upbeat forward guidance outweigh the small fourth-quarter earnings and revenue miss
Similar Companies in Healthcare
Other companies in the same sector with AI ratings